InvestSMART

PainChek Ltd (ASX:PCK)

ALERT: Price-sensitive ASX Announcement for PCK
Current share price for PCK : $0.098 -0.007 (-6.67%)+
Announcement
Release
29 Jul 2026 9:58AM
Price at Release
$0.105
Full Release
download
Summary
PainChek Ltd's quarterly activities report for the period ending 30 June 2026 highlights significant growth and strategic advancements. The company's implemented Annual Recurring Revenue (ARR) increased by 5.9% to $4.46 million, with a notable increase in customer receipts by 27% to $1.284 million, reflecting successful customer activations. PainChek has secured its first commercial deployments in the US under a master services agreement with Sabra Health Care REIT, facilitating a potential rollout across 20,000 US beds. The report also notes a net cash outflow improvement to $1.791 million, supported by a $5.5 million convertible note financing. PainChek's expansion is further bolstered by a $1.123 million R&D Tax Incentive refund post-quarter end. The company aims to enhance its commercial execution, focusing on activating licences and expanding its footprint in North America.
Key Points
  • Implemented ARR increased by 5.9% to $4.46 million.
  • Customer receipts rose by 27% to $1.284 million quarter-on-quarter.
  • First commercial deployments in the US under Sabra agreement initiated.
  • Net operating cash outflow improved to $1.791 million.
  • Received a $1.123 million R&D Tax Incentive refund after the quarter's end.
  • Focus on commercial execution and expansion in North America.
  • Increased customer sites to 1,990, maintaining 85% retention.
  • PainChek Adult received FDA De Novo clearance in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.